Skip to main content

Table 5 Factors influencing MSI testing in all CRC patients

From: Analysis of factors influencing molecular testing at diagnostic of colorectal cancer

  MSI testing
N = 138/1269 (10.9%)
Univariate analysis
P-Value
Multivariate analysis
Odds ratio IC 95% P-Value
Age (years)   < 0.0001    < 0.0001
  > 75 10 / 553 (1.8%)   1 Ref  
 60–75 46 / 508 (9.1%)   5.77 2.80–11.89  
  < 60 82 / 208 (39.4%)   59.6 27.82–127.85  
Sex   0.88    0.21
 Women 62 / 578 (10.7%)   1 Ref  
 Men 76 / 691 (11.0%)   0.75 0.47–1.18  
Site of the primary tumour   0.53    
 Rectum 31 / 309 (10.0%)     
 Right colon 44 / 437 (10.1%)     
 Left colon 63 / 523 (12.1%)     
TNM stage   < 0.001    0.0001
 I 6 / 219 (2.7%)   1 Ref  
 II 37 / 380 (9.7%)   8.62 3.17–23.41  
 III 49 / 380 (12.9%)   7.96 3.00–21.12  
 IV 46 / 290 (15.9%)   8.79 3.29–23.48  
Tumour grade (MD = 173)   0.34    
 Well 55 / 436 (12.6%)     
 Moderate 56 / 576 (9.7%)     
 Poor 9 / 84 (10.7%)     
Geographical area of primary treatment (MD = 4)   < 0.0001    < 0.0001
 Charente-Maritime 3 / 392 (0.8%)   1 Ref  
 Charente 21 / 226 (9.3%)   17.08 4.78–61.00  
 Deux-Sèvres 19 / 227 (8.4%)   13.98 3.89–50.24  
 Vienne 80 / 301 (26.6%)   69.59 20.51–236.01  
 Outside the region 15 / 119 (12.6%)   13.53 3.64–50.29  
Status of the center (MD = 4)   < 0.0001a    
 Public Hospital 36 / 551 (6.5%)  
 Private hospital 47 / 512 (9.2%)     
 University hospital 55 / 202 (27.2%)     
  1. 95% CI 95% confidence interval, NA not available, MD missing data, Ref reference
  2. aNot retained in the final multivariate model